Neuroone Medical Technologies (NMTC) Liabilities and Shareholders Equity (2016 - 2026)
Neuroone Medical Technologies filings provide 15 years of Liabilities and Shareholders Equity readings, the most recent being $7.9 million for Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity rose 76.48% to $7.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $38.0 million, a 79.19% increase, with the full-year FY2025 number at $10.8 million, up 100.85% from a year prior.
- Liabilities and Shareholders Equity hit $7.9 million in Q1 2026 for Neuroone Medical Technologies, down from $8.6 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $14.1 million in Q1 2022 to a low of $4.5 million in Q1 2025.
- Median Liabilities and Shareholders Equity over the past 5 years was $7.9 million (2026), compared with a mean of $8.2 million.
- Biggest five-year swings in Liabilities and Shareholders Equity: crashed 50.24% in 2023 and later surged 120.24% in 2025.
- Neuroone Medical Technologies' Liabilities and Shareholders Equity stood at $9.7 million in 2022, then crashed by 39.73% to $5.8 million in 2023, then increased by 11.54% to $6.5 million in 2024, then skyrocketed by 32.08% to $8.6 million in 2025, then decreased by 8.31% to $7.9 million in 2026.
- The last three reported values for Liabilities and Shareholders Equity were $7.9 million (Q1 2026), $8.6 million (Q4 2025), and $10.8 million (Q3 2025) per Business Quant data.